Parry-Jones, Adrian RStocking, KatieMacLeod, Mary JoanClarke, BrianWerring, David JMuir, Keith WVail, Andy2023-10-092023-10-092023-09Parry-Jones, A R, Stocking, K, MacLeod, M J, Clarke, B, Werring, D J, Muir, K W & Vail, A 2023, 'Phase II randomised, placebo-controlled, clinical trial of interleukin-1 receptor antagonist in intracerebral haemorrhage : BLOcking the Cytokine IL-1 in ICH (BLOC-ICH)', European Stroke Journal , vol. 8, no. 3, pp. 819-827. https://doi.org/10.1177/239698732311852082396-9873RIS: urn:A7A7340966C98A7D0B0A62D6ED39CC1EORCID: /0000-0003-2115-8184/work/138945559unpaywall: 10.1177/23969873231185208https://hdl.handle.net/2164/21871Funding The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This report is independent research arising from a Clinician Scientist Award to APJ (CS-2014-14-005) supported by the National Institute for Health Research. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health. Anakinra (Kineret®) and placebo were provided free of charge by Swedish Orphan Biovitrum AB (publ) (Sobi) under an Investigator Initiated Study Agreement. Sobi was not involved in the design or conduct of the study, data collection and analysis, or preparation of the manuscript. We are grateful to Sobi for supplying study drug and the NIHR Comprehensive Research Network and clinical teams at the BLOC-ICH sites. We are grateful to the members of the Trial Steering Committee and Independent Data Safety and Monitoring Committee (see Supplemental Materials for committee members).9362857engintracerebral hemorrhageinterleukin-1 receptor antagonistanakinraClinical trialRC Internal medicineNational Institute for Health Research (NIHR)CS-2014-14-005Supplementary InformationRCJournal article10.1177/2396987323118520883